Biosimilar Manufacturing solution center

  1. Optimizing Process Efficiency In Upstream Manufacturing

    Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency - a key goal for biopharmaceutical production.

  2. Chasing The Biopharma Market

    From new customer bases and vaccines to biosimilars and antibodies: what are the emerging trends and hot topics in biopharma, and how can companies take advantage of them in order to succeed?

  3. Speed Biologics To Clinical Trials Faster

    If your business strategy doesn’t fully align with your organization’s capabilities in terms of expertise, capacity, and resources, it might be wise to consider outsourcing to a biologics CDMO for speed to market.

  4. What Biosimilar Metamorphoses Are In Store For 2019?

    In the second of this three-part "Ask the Board" series, Biosimilar Development's editorial board members discuss their predictions on how biosimilar development, market access, commercialization efforts, and regulatory and reimbursement policies will evolve in 2019.

  5. Dancing In The Bioprocessing Ballroom: Voices Of Experience

    Single-use technology is well-established and made its way into commercial licensed facilities, but there is more innovation in this field which will enhance its versatility into new markets and technologies.

  6. Staying Flexible In Biomanufacturing

    The concept of optionality is key to staying flexible in biomanufacturing by keeping your options open and having multiple pathways to take while navigating through this highly uncertain environment. 

  7. Evolution Of Single-Use Bioprocessing Into BioPharm 4.0

    Biopharma manufacturers seek dynamic processing economics that address the paradigm shift from blockbuster drugs with established production schemes to small-scale manufacturing and innovative tech.

  8. Amgen’s Digital Transformation: Linking Raw Material Data From Suppliers To Patients

    Using its Supplier Relationship Excellence (SRE) program, Amgen opened the lines of communication with suppliers and created a feedback loop where data can be shared to better understand operational performance. 

  9. Market Research Report: Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)

    A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of the market. ISR’s Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition) goes into depth on one of the most important aspects of biosimilars: manufacturing.

  10. How Biopharma Is Capitalizing On The Antibody Boom

    Antibodies continue to dominate. Analyzing the strategies employed by successful players in the field could provide invaluable lessons for those hoping to enter it.